COMPOSITION FOR DETECTION circulating biomarkers integrin beta-3 AND METHODS FOR DETECTION OF CANCER AND EVALUATION presence or tumor progression, drug resistance and tumor stem

摘要

Provided are compositions, including kits, and methods comprising use of a biomarker β3 integrin, including the αvβ3 integrin, for detecting circulating tumor cells (CTCs), tumor stem cells, extracellular vesicles (EV), including exosomes and microvesicles, that are released by CTCs or cancer cells, as well as the tumor from which the CTCs or EVs derive, and to make a patient prognosis, and to assess tumor progression, and drug resistance (for example, resistance to tyrosine kinase inhibitors), e.g., for several cancers including: breast, colon, lung and pancreatic cancers. In alternative embodiments, a patient fluid sample, e.g., a blood, serum, urine, CSF or other sample, is taken and used to detect cancer stem cells, EVs- and/or CTCs-comprising β3 integrin and/or a αvβ3 integrin. Provided are compositions, including kits, and methods and uses of the biomarker β3 integrin for anti-cancer drug design. In alternative embodiments, applications of compositions, including kits, and methods and uses as provided herein include conjugation of an imaging or therapeutic agent to an antibody targeting integrin β3 for detection and/or targeted destruction of integrin β3 expressing cancer stem cells and/or CTCs.